A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
Creators: name: Harding, James J
name: Fan, Jia
name: Oh, Do-Youn
name: Choi, Hye Jin
name: Kim, Jin Won
name: Chang, Heung-Moon
name: Bao, Lequn
name: Sun, Hui-Chuan
name: Macarulla, Teresa
name: Xie, Feng
name: Metges, Jean-Phillippe
name: Ying, Jie'er
name: Bridgewater, John
name: Lee, Myung-Ah
name: Tejani, Mohamedtaki A
name: Chen, Emerson Y
name: Kim, Dong Uk
name: Wasan, Harpreet
name: Ducreux, Michel
name: Bao, Yuanyuan
name: Lindsey, Stacie
name: Bachini, Melinda
name: Morement, Helen
name: Boyken, Lisa
name: Ma, Jiafang
name: Garfin, Phillip
name: Pant, Shubham
Publisher: name: Taylor & Francis
Year: 2024
Subjects: Pharmacology
Biotechnology
Biological Sciences not elsewhere classified
Cancer
Science Policy

description: Researchers wanted to study whether the research drug zanidatamab could help people with a type of cancer called biliary tract cancer. In some people, biliary tract cancer cells make extra copies of a gene called HER2 (also called ERBB2). This is known as being HER2-amplified. Zanidatamab is an antibody designed to destroy cancer cells that have higher-than-normal HER2 protein or gene levels. Zanidatamab is currently under research and is not yet approved for any diseases. Participants in this phase 2b clinical study had tumors that were HER2-amplified and at the advanced or metastatic stage. Participants also had cancer which had become worse after previous chemotherapy or had side effects that were too bad to continue chemotherapy. They also had to meet other requirements to be enrolled. Researchers measured the amount of HER2 protein in the tumor samples of the participants who were enrolled. There were 80 participants with tumors that were both HER2 amplified and had higher-than-normal HER2 protein amounts (considered to be ‘HER2-positive’). There were 7 participants with tumors that were HER2-amplified, but had little-to-no levels of the HER2 protein (considered to be ‘HER2-low’). All participants in the study were treated with zanidatamab and no other cancer treatments once every 2 weeks. In the HER2-positive group, 33 of 80 (41%) participants had their tumors shrink by 30% or more of their original size. In half of these participants, their tumors did not grow for 13 months or longer. No participant in the HER2-low group had their tumors shrink by 30% or more. In total, 63 of 87 participants (72%) had at least one side effect believed to be related to zanidatamab treatment. Most side effects were mild or moderate in severity. No participant died from complications related to zanidatamab. Diarrhea was one of the more common side effects and was experienced by 32 of 87 participants (37%). Side effects related to receiving zanidatamab through the vein, such as chills, fever, or high blood pressure, were experienced by 29 of 87 participants (33%). The results of this study support the potential for zanidatamab as a new therapy for people with HER2-positive biliary tract cancer after they had already received chemotherapy. More research is occurring to support these results. <b>Clinical Trial Registration:</b>NCT04466891 (HERIZON-BTC-01 study) The HERIZON-BTC-01 study revealed zanidatamab as a potentially effective treatment for HER2-positive biliary tract cancer after standard chemotherapy fails. Read more in the lay summary by @hardingjjmd, @DrShubhamPant, and coauthors. #BiliaryTractCancer #HER2 #zanidatamab A PDF version of this infographic is available as supplemental material.